AMF Share Price

Open 0.05 Change Price %
High 0.05 1 Day 0.00 0.00
Low 0.05 1 Week 0.00 0.00
Close 0.05 1 Month 0.00 0.00
Volume 23840 1 Year 0.00 0.00
52 Week High 14.85
52 Week Low 9.75
AMF Important Levels
Resistance 2 0.05
Resistance 1 0.05
Pivot 0.05
Support 1 0.05
Support 2 0.05
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
MFC 24.30 2.57%
MFC 24.30 2.57%
MFC 24.30 2.57%
MFC 24.30 2.57%
More..
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
ST 0.02 100.00%
ST 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TPL 0.02 100.00%
TPL 0.02 100.00%
QEC 0.74 42.31%
QEC 0.74 42.31%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
HE 0.04 -20.00%
HE 0.04 -20.00%
HBP 1.35 -12.90%
HBP 1.35 -12.90%
NKO 0.08 -11.11%
NKO 0.08 -11.11%
NKO 0.08 -11.11%
CCM 0.08 -11.11%
CCM 0.08 -11.11%
More..

Amorfix Life Sciences Ltd (TSE: AMF)

AMF Technical Analysis 2
As on 13th Jul 2015 AMF Share Price closed @ 0.05 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.16 & Buy for SHORT-TERM with Stoploss of 0.04 we also expect STOCK to react on Following IMPORTANT LEVELS.
AMF Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
AMF Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Medical Laboratories & Research
Offical website http://www.amorfix.com
AMF Address
AMF
3403 American Drive
Mississauga, ON L4V 1T4
Canada
Phone: 416-847-6898
Fax: 416-847-6899
Interactive Technical Analysis Chart Amorfix Life Sciences Ltd ( AMF TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Amorfix Life Sciences Ltd
AMF Business Profile
Amorfix Life Sciences Ltd. develops therapeutics and diagnostic devices for misfolded protein diseases. It develops antibodies and vaccines that recognize misfolded protein in amyotrophic lateral sclerosis (ALS), as well as in various CJD and cancer. The company's diagnostic programs include EP-AD CSF Diagnostic Test, an assay for the detection of the aggregated form of Aß in human cerebrospinal fluid and mild cognitive impairment; A4, an ultra-sensitive assay for detecting aggregated Aß in animal models of Alzheimer's disease (AD); blood test for use as a diagnostic tool for ALS; and liver cancer screening assay. It also offers custom assay development services. The company also has strategic alliances with Epitomics Inc. to develop immunotherapeutics to various proteins; and license agreement with Biogen Idec for developing therapeutics to treat ALS. Amorfix Life Sciences Ltd. was founded in 2004 and is based in Mississauga, Canada.